{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:34:49Z","timestamp":1776850489425,"version":"3.51.2"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>Steady-state plasma phenobarbital (PB) concentrations (n = 671) were measured\nin 438 inpatients. There was a significant relationship between age and PB dose ratio (concentration\/\ndose or 1\/clearance) for monotherapy patients; the dose ratio declined in the first\nyear of life, but the dose ratio increased after age 1. The dose ratios were significantly higher\nin patients receiving PB in combination with other antiepileptic drugs. However, neither sex\nnor formulations used (tablet, elixir and intravenous) had any influence on the PB dose ratio.\nThe age-dose-concentration relationships indicate that children, especially those under 11\nyears of age, may require maintenance PB doses more than 5 mg\/kg\/day to achieve the\ncommonly recommended 'therapeutic' concentration range (10-40 mg\/l).<\/jats:p>","DOI":"10.1159\/000457502","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:08:31Z","timestamp":1502471311000},"page":"79-87","source":"Crossref","is-referenced-by-count":3,"title":["Phenobarbital Doses Necessary to Achieve 'Therapeutic'\nConcentrations in Children"],"prefix":"10.1159","author":[{"given":"Yasuhiro","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.D.","family":"Walson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457502","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:34:36Z","timestamp":1776846876000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457502"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457502","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}